<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044756</url>
  </required_header>
  <id_info>
    <org_study_id>Omit</org_study_id>
    <nct_id>NCT03044756</nct_id>
  </id_info>
  <brief_title>Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger</brief_title>
  <official_title>Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omitting the GnRH antagonist on the day of the trigger can be cost effective and more
      convenient to the women. We will study the impact of omitting the antagonist dose in a
      prospective randomized trial
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of retrieved oocytes</measure>
    <time_frame>One Month</time_frame>
    <description>total number and maturation of the retrieved oocytes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pituitary Downregulation</condition>
  <arm_group>
    <arm_group_label>-ve arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>+ve arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omit Citrotide 0.25 dose on the day of triggering of ovulation</intervention_name>
    <description>Omit Citrotide 0.25 dose on the day of triggering of ovulation</description>
    <arm_group_label>-ve arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All antagonist cycle ivf who agree to participate

        Exclusion Criteria:

          -  expected poor responders.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Osama Abdalmageed</name>
      <address>
        <city>Assiut</city>
        <state>Non-US/Non-Canadian</state>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama Abdalmageed</last_name>
      <phone>1007972027</phone>
      <email>drosamast1981@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osama Abdalmageed</name>
      <address>
        <city>Assiut</city>
        <state>Non-US/Non-Canadian</state>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama Abdalmageed</last_name>
      <email>drosamast1981@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Chang HJ, Lee JR, Jee BC, Suh CS, Lee WD, Kim SH. Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study. Clin Exp Reprod Med. 2013 Jun;40(2):83-9. doi: 10.5653/cerm.2013.40.2.83. Epub 2013 Jun 30.</citation>
    <PMID>23875164</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Osama Saber Thabet Abdalmageed</investigator_full_name>
    <investigator_title>Lecturer of OBGYN, Women Health Hospital, Assiut Univerisity</investigator_title>
  </responsible_party>
  <keyword>GnRH antagonist</keyword>
  <keyword>Pituitary downregulation</keyword>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The regulations in Assiut University do not allow protected patient data sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

